



Medicines & Healthcare products
Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

[MHRA Website](#)

Our Ref: **FOI2026/00550**

17 June 2026

Dear [REDACTED]

Thank you for your Freedom of Information (FOI) request received on 19 May. You wrote:

Teva requests innovator (Eliquis) RMP for apixaban in order to compare Teva RMP (Liver injuries FUQ) to innovator's RMP. This is advance of RMP update which will be submitted subsequently.

MHRA Response

We confirm that we hold the information you have requested and a copy of the RMP for Eliquis is attached.

Section 40 (2) – Personal Information

We are unable to provide you with some of the information requested as it constitutes personal data of someone other than yourself and as such, it is being withheld in accordance with section 40(2) of the Freedom of Information Act.

Section 40(2) exempts information in response to a request if it is personal data belonging to an individual other than the requester and it satisfies one of the conditions listed in the legislation. In this case the condition contained in section 40(3A)(a) applies - that disclosure would breach one of the data protection principles, specifically that "Personal data shall be processed lawfully, fairly and in a transparent manner...".

We do not consider that disclosing this information is necessary or justified in order to satisfy your information request and the requirements of the FoI Act. In relation to this request, we consider that there is no strong legitimate interest that would override the prejudice to the rights and freedoms of the data subject.

Personal data are subject to UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018

MHRA maintains the following policy on disclosure of personal information:

"All personal information held in MHRA records is regarded as confidential. Information will not normally be disclosed to third parties without the consent of the person concerned. Information may normally be disclosed without consent to meet statutory requirements; to

comply with a court order; to prevent duplication of payments from public funds; or where there is a compelling public interest in making the disclosure."

All disclosures made by MHRA, in order to be considered authorised must be able to demonstrate that at least one of the above criteria apply.

Under the FoI Act, MHRA is not obliged to confirm or deny that it holds personal information about third parties, but in any event, even if was held, the Agency would not disclose personal information to you about Eliquis RMP.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>